background preloader

PharmMed Intro

Facebook Twitter

Countries and Territories. Australian Government Department of Health. Current status The situation is changing rapidly.

Australian Government Department of Health

Symptoms If you have serious symptoms such as difficulty breathing, call 000 for urgent medical help. Symptoms include: Do androids dream of electric lawsuits? Current IP law ill-suited for AI in drug discovery, panelist says. L-R: Richard Assmus, David Opderbeck, Lori Bennett, Brian Nolan As more companies use artificial intelligence and machine learning in the process of drug discovery and development, that raises a big question: Who owns the intellectual property?

Do androids dream of electric lawsuits? Current IP law ill-suited for AI in drug discovery, panelist says

That emerged as a significant topic of discussion in a panel Thursday afternoon at the Hot Topics in Life Sciences Law symposium, sponsored by the law firm Mayer Brown. The symposium took place at the Seton Hall Law School in Newark, New Jersey. Mayer Brown partner Brian Nolan moderated the panel, which included fellow Mayer Brown partner Richard Assmus; Lori Bennett, general counsel of Aetion; and David Opderbeck, a professor of law at Seton Hall. “It’s almost like there’s something new going on here that current IP law is not well-suited to protect,” said panelist Richard Assmus, a partner at Mayer Brown’s Chicago office. Disruption in Health Care (and Sleep Medicine): “It’s the End of the World as We Know it…and I Feel Fine.”

Timing and assimilation of new technology adoption in healthcare. Telehealth and Medicine Today. SUBSCRIBE to TMT TMT is an open-access publication and does not require subscriptions.

Telehealth and Medicine Today

We invite you to to receive announcements and updates on the latest publications as they are pushed live. Top 10 Blockchain Predictions for the (Near) Future of Healthcare. To review blockchain lessons learned in 2018 and near-future predictions for blockchain in healthcare, Blockchain in Healthcare Today (BHTY) asked the world's blockchain in healthcare experts to share their insights.

Top 10 Blockchain Predictions for the (Near) Future of Healthcare

Here, our internationally-renowned BHTY peer-review board discusses their major predictions.Based on their responses, presented in detail below, ten major themes (Table ) for the future of blockchain in healthcare will emerge over the 12 months. This following paragraph has been corrected (page 3, first paragraph) from: "Fourth, with over 1000 insurance companies in the country, filling out paperwork to documentprovider training and licensure is a nightmare. The Synaptic Health Alliance aims to simplifythis process by putting all credentialing information on a distributed public ledger for all stakeholders to access.1" The era of expontential improvement in healthcare. Thoughts from the Centre. By Karen Taylor and Krissie Ferris, Centre for Health Solutions Since 2008, the Deloitte US Center for Health Solutions has polled a nationally representative sample of US adults (18 and older) about their experiences and attitudes related to their health, health insurance, and health care.1 Earlier this year we helped the US Center design a global survey to help understand what consumers value most about healthcare, and their appetite for digital innovations, including their willingness to share their personal health data.

Thoughts from the Centre

The US Center collected primary data through an online survey, fielded between May and June 2019, in seven countries (Australia, Canada, Denmark, Germany, Netherlands Singapore and the UK). It then compared their responses to responses from the US consumer survey conducted in 2018. The US Centre launched their report on the survey last week.2 This week’s blog is our take on the key findings for the UK. Continue reading. Ten years on: The future of biopharma innovation. The growing importance of biologics In our 2010 analysis, 67 per cent of the assets in our original cohort’s pipeline were traditional small molecules; in our 2019 analysis, the proportion of small molecules had fallen to 43 per cent.

Ten years on: The future of biopharma innovation

Life Sciences and Health Care Software Solutions – ConvergeHEALTH. Intelligent Biopharma Series. Deloitteukunlockingrdproductivity1582624324270. Deloitteukmeasuringthereturnrdtenyearson1582561071944. Deloitteukintelligentbiopharmaforgingthelinks1582561041941. Deloitteukglobalsciencesoutlook20201582560970619. Deloitteukbiotechinabox1582560937906.

Thefutureofbiopharmawebinarslidedeck1582738607674. 203 Startups Using Artificial Intelligence in Drug Discovery. Welcome to what I hope is a comprehensive list of startups using machine learning to research and develop drugs.

203 Startups Using Artificial Intelligence in Drug Discovery

Deloitte uk ten years on measuring return on pharma innovation report 2019. Changing R&D models in research-based pharmaceutical companies. Eli Lilly is a pioneer and leader in the crowdsourcing field in the pharmaceutical industry.

Changing R&D models in research-based pharmaceutical companies

It initiated several crowdsourcing initiatives such as Innocentive® or YourEncore- both are now operated independently. YourEncore (www.yourencore.com) is an expert network working in technology industry, such as life science, consumer and food industries, that support companies to access expert know-how to help to solve the companies’ problems. An agile pharma R&D operating model. Today biopharmaceutical innovation is advancing at breakneck pace, with opportunities to address diseases once considered intractable using technologies that were previously restricted to the realm of science fiction.

An agile pharma R&D operating model

These advances have delivered measurable impact to the lives of hundreds of millions: for instance, US life expectancy at birth increased by 3.4 years between 1990 and 2015. Moreover, there is no sign of this innovation slowing. The past ten years have been exciting ones: we have seen the evolution of immuno-oncology from a niche therapy to mainstream (PD1 therapies are forecast to be worth $30 billion within five years ), the dawn of cellular therapies (with over 500 clinical assets ), and the promise of gene therapies able to target individual mutations (such as for severe combined immune deficiency). We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. 20 Predictions for the Next 20 Years - KPMG Australia. The Basics of the Immune System. Pharmacology Education Project. d41573 020 00001 7. Q3 2019 Data Report - Alliance for Regenerative Medicine.

Pitcher Partners Australian M&A 2020 FINAL LR. Five megatrends implications. Pwc pharma success strategies. 01 Business Strategy. Why Pharma Strategic Planning Reduces Productivity And How To Fix It. As is often the case in pharma, Emma Walmsley, the CEO of Glaxo, soon after taking office announced a reorganization of R&D, no doubt the product of a thoughtful strategic plan.

Why Pharma Strategic Planning Reduces Productivity And How To Fix It

As the Wall Street Journal described the program in March of this year, “Ms. Walmsley has replaced top managers, pruned the ranks of scientists and shut down clinical trials to narrow the drug-development focus.” A reorganization that one observer described as on a scale “unprecedented, even for pharma.” Ms. Walmsley is by no means alone. But this is pharmaceuticals… The need (compulsion?) The Google dictionary defines stochastic as “randomly determined; having a random probability distribution or pattern that may be analyzed statistically but may not be predicted precisely.”

The plot shows the level of sales achieved on the x-axis from 0 to multiple billions, and the number of drugs with that level of sales on the y-axis. A stochastic enterprise doesn’t lend itself to planning in the conventional sense. A critical makeover for pharmaceutical companies: Overcoming industry obstacles with a cross-functional strategy. This is a difficult time for global pharmaceutical companies — so difficult, in fact, that many are reconsidering their business models.

The litany of concerns that pharmaceutical companies face includes payors tightening up on cost management, strained government healthcare budgets, the need to understand and adopt new technologies, and challenges to their traditional pricing mechanisms by empowered stakeholders, from patients to payors. Moreover, the regulatory maze in many parts of the world is tough to navigate, with unique rules and varied outcomes depending on national policies, issues, and bureaucratic processes.

Compounding the external obstacles, however, is the internal culture of most pharma companies. This is an industry that has long operated through disparate components — silos that separated R&D, commercial, production, and supply chain. This report offers a detailed framework for implementing a successful critical team strategy. Click here for the full report. Shifts in pharma’s 2020 digital health landscape.

About the author: Naomi Fried, PhD, is the CEO of Health Innovation Strategies, which provides digital health strategy and innovation-program design and optimization consulting to healthcare stakeholders including pharma, payers and providers. Her previous positions include the first chief innovation officer at Boston Children’s Hospital, Biogen’s VP of innovation and external partnerships, and VP of innovation and advanced technology at Kaiser Permanente. Follow Naomi on Twitter @NaomiFried. In 2019, a number of big pharma companies experienced growing pains around their engagement with digital health start-ups.

Eight Biopharma Trends to Watch in 2020: In the year ahead, the industry will be alert to political developments, commercial opportunities, and technological breakthroughs: Genetic Engineering & Biotechnology News: Vol 40, No 1. Role of a CMO in advanced therapy clinical and commercial manufacture. Julie Warner, VP of Regulatory Affairs at Boyds, has co-edited the latest issue of TOPRA‘s Regulatory Rapporteur. In this issue, there is an article co-authored by Julie and Kathryn Parsley of Gyroscope Therapeutics, entitled ‘The critical role of a CMO in advanced therapy clinical and commercial product manufacture’ which considers some of the complexities of ATMP manufacture and recommends aspects to consider when selecting a CMO. The following article was published in the Regulatory Rapporteur, Volume 17, Number 2, February 2020.

Recent years have seen a significant increase in the number of advanced therapy medicinal products (ATMPs) both in development and reaching the market (see Table 11 and 2). 2020 GFCC Annual Meeting and Global Innovation Summit. Pharmaceutical Industry in China: Policy, Market and IP. 6.1 Similarities and Differences It will be beneficial to compare the development of pharmaceutical industries of China and India. The two countries are similar in many aspects, such as most condensed population (altogether, 40% of the population in the world), developing mode similar from an agricultural-based economy to gradually industrial economies, and most importantly, both are in the fastest growth rate in economic performance.

How technological innovation affects the structure of an industry: entrepreneurship evolution in the biotechnology and pharmaceutical industry since 1980: Technology Analysis & Strategic Management: Vol 28, No 6. Spin-Off and Innovation in the Pharmaceutical Industry - Enzo Peruffo, Luca Pirolo, Maria Elena Nenni, 2014. 1. Introduction. Astra finds no fit for rare diseases in latest big pharma spin-out. Astrazeneca gave birth to the latest big pharma baby today, unveiling a relatively well-stocked biotech focused on inflammation and autoimmune conditions. R&D Spin-outs in the Pharmaceutical Industry. Improved Protein Structure Prediction Using Potentials From Deep Learning - PubMed.

Protein structure prediction can be used to determine the three-dimensional shape of a protein from its amino acid sequence1. This problem is of fundamental importance as the structure of a protein largely determines its function2; however, protein structures can be difficult to determine experimentally. Considerable progress has recently been made by leveraging genetic information. New drug candidate created by AI in ‘world first’ Newsroom - AusBiotech Ltd. Regenerative medicine is poised for continued expansion in 2020, after the latest global industry briefing reveals another year of significant growth, and total global financings the second highest yet. Why Drugs Fail in Late Stages of Development: Case Study Analyses From the Last Decade and Recommendations - PubMed.

Artificial Intelligence in Drug Development: Present Status and Future Prospects - PubMed. Organ-on-chip Models: Implications in Drug Discovery and Clinical Applications - PubMed. Technological Advances in Preclinical Drug Evaluation: The Role of -Omics Methods - PubMed. An Update on Drug Repurposing: Re-written Saga of the Drug's Fate - PubMed. Drug repurposing is an unconventional drug discovery approach to explore new therapeutic benefits of existing, shelved and the drugs in clinical trials. This approach is currently emerging to overcome the bottleneck constraints faced during traditional drug discovery in grounds of financial support, timeline and resources.

What Is Value in Health Care? 's 23rd Annual Global CEO Survey - Navigating the rising tide of uncertainty. Technologies to watch in 2020. I’m Talking to You-Mab—How to Pronounce the New, Unpronounceable Pharmaceuticals. Pronunciation guide. Ambition Zero Carbon. Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine. Deloitte uk ten years on measuring return on pharma innovation report 2019. Larry Fink CEO Letter.